ESR1 and breast carcinoma: To determine whether INPP4B overexpressing ER+ breast cancer cells exhibit enhanced sensitivity to Wnt-targeted therapies, four small molecule Wnt inhibitors that target different Wnt pathway components and are clinically approved and/or undergoing clinical trials were evaluated.